ABSTRACT
Natto, a traditional Japanese fermented soybean food, is well known to be nutritious and beneficial for health. In this study, we examined whether natto impairs infection by viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as bovine herpesvirus 1 (BHV-1). Interestingly, our results show that both SARS-CoV-2 and BHV-1 treated with a natto extract were fully inhibited infection to the cells. We also found that the glycoprotein D of BHV-1 was shown to be degraded by Western blot analysis and that a recombinant SARS-CoV-2 receptor-binding domain (RBD) was proteolytically degraded when incubated with the natto extract. In addition, RBD protein carrying a point mutation (UK variant N501Y) was also degraded by the natto extract. When the natto extract was heated at 100 °C for 10 min, the ability of both SARS-CoV-2 and BHV-1 to infect to the cells was restored. Consistent with the results of the heat inactivation, a serine protease inhibitor inhibited anti-BHV-1 activity caused by the natto extract. Thus, our findings provide the first evidence that the natto extract contains a protease(s) that inhibits viral infection through the proteolysis of the viral proteins.
Subject(s)
COVID-19 Drug Treatment , Glycine max/chemistry , Plant Extracts/pharmacology , SARS-CoV-2/drug effects , Soy Foods , Animals , COVID-19/metabolism , COVID-19/pathology , COVID-19/virology , Cattle , Cells, Cultured , Chlorocebus aethiops , Herpesviridae Infections/drug therapy , Herpesviridae Infections/metabolism , Herpesviridae Infections/pathology , Herpesviridae Infections/virology , Herpesvirus 1, Bovine/drug effects , Herpesvirus 1, Bovine/isolation & purification , Herpesvirus 1, Bovine/pathogenicity , Humans , Plant Extracts/chemistry , SARS-CoV-2/isolation & purification , SARS-CoV-2/pathogenicity , Viral Proteins/antagonists & inhibitors , Viral Proteins/metabolismABSTRACT
Human herpesviruses are known to induce a broad spectrum of diseases, ranging from common cold sores to cancer, and infections with some types of these viruses, known as human oncogenic herpesviruses (HOHVs), can cause cancer. Challenges with viral latency, recurrent infections, and drug resistance have generated the need for finding new drugs with the ability to overcome these barriers. Berberine (BBR), a naturally occurring alkaloid, is known for its multiple biological activities, including antiviral and anticancer effects. This paper comprehensively compiles all studies that have featured anti-HOHV properties of BBR along with promising preventive effects against the associated cancers. The mechanisms and pathways induced by BBR via targeting the herpesvirus life cycle and the pathogenesis of the linked malignancies are reviewed. Approaches to enhance the therapeutic efficacy of BBR and its use in clinical practice as an anti-herpesvirus drug are also discussed.
Subject(s)
Antiviral Agents/therapeutic use , Berberine/therapeutic use , Carcinogenesis/drug effects , Herpesviridae Infections/drug therapy , Herpesviridae/drug effects , Neoplasms/drug therapy , Neoplasms/virology , Animals , Clinical Trials as Topic , Herpesviridae/classification , Herpesviridae/pathogenicity , Herpesviridae Infections/complications , Humans , Inflammation/drug therapy , Inflammation/virology , Mice , Virus Latency/drug effects , Virus Replication/drug effectsABSTRACT
A captive loggerhead turtle (Caretta caretta) of unknown sex, 3 years of age, presented with bilateral mucoid secretions, severe chemosis, conjunctival hyperemia, and globe retraction. The animal was evaluated ophthalmologically and systemically, and hematological, microbiological, and conjunctival cytological and biopsy samples were collected for complementary diagnosis. The histopathological examination showed amphophilic intranuclear inclusions associated with severe inflammatory infiltrate. The diagnosis of Chelonid alphaherpesvirus 5 (ChAHV 5) was confirmed with end point PCR. Following systemic treatment with L-lysine, acyclovir and vitamin A, the ocular signs resolved. No amphophilic intranuclear inclusions were seen in a follow-up biopsy 5 months later, and there has been no recurrence of clinical ophthalmic signs during a 4-year follow-up. It is suggested that ChAHV 5 be considered as a differential diagnosis in captive marine turtles that present for conjunctival disease other than fibropapillomatosis.
Subject(s)
Alphaherpesvirinae , Conjunctivitis, Viral/veterinary , Herpesviridae Infections/veterinary , Turtles , Animals , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/drug therapy , Conjunctivitis, Viral/pathology , Herpesviridae Infections/diagnosis , Herpesviridae Infections/drug therapy , Herpesviridae Infections/virology , Lysine/therapeutic use , Polymerase Chain Reaction/veterinaryABSTRACT
Cyprinid herpesvirus 2 (CyHV-2), which infects silver crucian carp including goldfish (Carassius auratus auratus) and Crucian carp (Carassius auratus gibelio) with high mortality, is an emerging viral pathogen worldwide. Previous studies showed that berberine (BBR), a bioactive plant-derived alkaloid, demonstrated potential antiviral actions against many different viruses. Here, we assessed the effect of berberine hydrochloride (BBH) on the replication of CyHV-2 in vitro and in vivo. Cytotoxicity assay indicated that 5-25 µg/mL BBH was non-toxic to the RyuF-2 cells. In viral inhibition assays, real time PCR was employed to titrate the genomic copy number of progeny virus, real time RT-PCR was applied to monitor the transcriptional levels of viral genes, and Western blot analysis was performed to detect the synthetic levels of viral proteins. The results demonstrated that BBH systematically impedes the viral gene transcription and suppressed the replication of CyHV-2 in RyuF-2 cells. In animal challenge test, BBH was confirmed to protect Crucian carps from CyHV-2 infection in a dose-dependent manner, which was supported by suppressed viral replication levels, reduced viral pathogenesis and higher survival rates. Furthermore, pharmacokinetics data of BBH in Crucian carp revealed its rapid absorption (Tmax of 1.5 h), suitable plasma half-life (t1/2z/h of 7-12 h depending on oral dosage), and dose-dependent drug exposure properties following oral administration (revealed by AUC0-t values). These findings shed light on repurposing BBH to treat CyHV-2 infections in silver crucian carp.
Subject(s)
Berberine/pharmacology , Berberine/pharmacokinetics , Carps/virology , Herpesviridae Infections/veterinary , Herpesviridae/drug effects , Virus Replication/drug effects , Administration, Oral , Animals , Cell Line , Cell Proliferation , Fish Diseases/drug therapy , Fish Diseases/virology , Herpesviridae/physiology , Herpesviridae Infections/drug therapy , Herpesviridae Infections/virology , Plant Extracts/pharmacologyABSTRACT
Human herpesviruses are among the most prevalent pathogens worldwide and have become an important public health issue. Recurrent infections and the emergence of resistant viral strains reinforce the need of searching new drugs to treat herpes virus infections. Cardiac glycosides are used clinically to treat cardiovascular disturbances, such as congestive heart failure and atrial arrhythmias. In recent years, they have sparked new interest in their potential anti-herpes action. It has been previously reported by our research group that two new semisynthetic cardenolides, namely C10 (3ß-[(N-(2-hydroxyethyl)aminoacetyl]amino-3-deoxydigitoxigenin) and C11 (3ß-(hydroxyacetyl)amino-3-deoxydigitoxigenin), exhibited potential anti-HSV-1 and anti-HSV-2 with selectivity index values > 1,000, comparable with those of acyclovir. This work reports the mechanism investigation of anti-herpes action of these derivatives. The results demonstrated that C10 and C11 interfere with the intermediate and final steps of HSV replication, but not with the early stages, since they completely abolished the expression of the UL42 (ß) and gD (γ) proteins and partially reduced that of ICP27 (α). Additionally, they were not virucidal and had no prophylactic effects. Both compounds inhibited HSV replication at nanomolar concentrations, but cardenolide C10 was more active than C11 and can be considered as an anti-herpes drug candidate including against acyclovir-resistant HSV-1 strains.
Subject(s)
Antiviral Agents/pharmacology , Cardenolides/pharmacology , Herpesvirus 1, Human/drug effects , Herpesvirus 2, Human/drug effects , Acyclovir/pharmacology , Animals , Antiviral Agents/chemical synthesis , Cardenolides/chemical synthesis , Chlorocebus aethiops , Drug Evaluation, Preclinical , Drug Resistance, Viral , Herpesviridae Infections/drug therapy , Humans , Vero CellsABSTRACT
The whole world is currently facing an unseen enemy, called coronavirus disease 2019 (COVID-19), which is causing a global pandemic. This disease is caused by a novel single-stranded enveloped RNA virus, known as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Although huge efforts are being made to produce effective therapies to combat this disease, it continues to be one of the greatest challenges in medicine. There is no doubt that herpesviruses are one of the most important viruses that infect humans and animals, and infections induced by these pathogens have developed into a great threat to public health. According to the currently available evidence, the correlation between herpesviruses and coronaviruses is limited to the induced complications following the infections. For instance, the inflammation that is induced at the sites of infection could tie these viruses to each other in a relationship. Another example, bovine herpesvirus 1, which is an important pathogen of cattle, can cause a severe respiratory infection; the same way in which SARS-CoV-2 affects humans. Considering the current circumstances related to the COVID-19 crisis, this editorial paper, which belongs to the Special Issue "Recent Advances in Herpesviruses Research: What's in the Pipeline?" aims to draw attention to some natural anti-herpesvirus alkaloid compounds, which have recently been proven to have excellent inhibitory efficacy against SARS-CoV-2 replication. Thus, this special focus is an attempt to hunt down various treatment options to combat COVID-19 based on repurposing drugs that are known to have multiple antiviral properties, including against herpesvirus.
Subject(s)
Alkaloids/pharmacology , Coronavirus Infections/drug therapy , Herpesviridae/drug effects , Plant Extracts/pharmacology , Pneumonia, Viral/drug therapy , Animals , Antiviral Agents/pharmacology , Betacoronavirus/drug effects , COVID-19 , Herpesviridae Infections/drug therapy , Humans , Pandemics , Plant Extracts/therapeutic use , SARS-CoV-2ABSTRACT
Infectious ocular disease, such as conjunctivitis, is common in cats and can be caused by several viruses and bacteria, either as a single infection or as co-infections. In this study, povidone-iodine (PVP-I), alone or compounded with hydroxyethyl cellulose (HEC), was investigated for its efficacy against these pathogens in vitro. Whilst PVP-I alone was effective at inhibiting feline herpesvirus type 1 (FHV-1), Chlamydia felis, and Mycoplasma felis, PVP-I with HEC exerted a synergistic inhibitory effect against FHV-1 and C. felis. In contrast, only minimal inhibition of feline calicivirus was observed. These results demonstrate that PVP-I, alone and in combination with HEC, is effective against some feline ocular pathogens when tested in cell lines in vitro. In vivo studies investigating the systemic safety, ocular tolerance, and clinical efficacy of this combination in cats would be necessary before it could be recommended as a therapy in affected cats.
Subject(s)
Anti-Infective Agents, Local/therapeutic use , Cat Diseases/drug therapy , Cellulose/analogs & derivatives , Conjunctivitis/veterinary , Ophthalmic Solutions/therapeutic use , Povidone-Iodine/therapeutic use , Animals , Anti-Infective Agents, Local/administration & dosage , Anti-Infective Agents, Local/pharmacology , Calicivirus, Feline/drug effects , Cat Diseases/microbiology , Cats , Cellulose/administration & dosage , Cellulose/therapeutic use , Chlamydia/drug effects , Chlamydophila Infections/drug therapy , Chlamydophila Infections/veterinary , Conjunctivitis/drug therapy , Drug Therapy, Combination , Female , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Male , Microbial Sensitivity Tests/veterinary , Mycoplasma/drug effects , Mycoplasma Infections/drug therapy , Mycoplasma Infections/veterinary , Ophthalmic Solutions/administration & dosage , Povidone-Iodine/administration & dosage , Povidone-Iodine/pharmacology , Treatment OutcomeABSTRACT
Equid herpesvirus 1 (EHV-1) is a pathogen of high economic importance in equine breeding operations around the world. EHV-1 infection causes respiratory, neurologic and reproductive disease. The absence of an efficient therapy has caught the attention of the scientific community and the therapeutic activities of natural products with its antivirals effects might be effective for the disease's treatment. Herein it was evaluated the prophylactic and therapeutic potential of quercetin and ethanolic extracts of Bacharis dracunculifolia formulations compared to Penciclovir® in an in vivo EHV-1 infection model. Six to seven-week-old female C57BL/6 mice were randomly organized into fifteen groups with six animals each. Ex-1 represents the treatment post-challenge groups to assess morbidity, mortality and weight variation. Ex-2 represents the animals that received treatment for 5â¯days post-challenge for lesion evaluation. In Ex-3 animals were treated prior to viral challenge to assess morbidity, mortality and weight variation. All mice in the treatment groups were challenged by intranasal inoculation of 3.0â¯×â¯105 TCID50 EHV-1. The quercetin and B. dracunculifolia treatment decreased morbimortality in post-challenge treatment (Ex-1) and EHV-1 related lesions (Ex-2). Treatment prior to viral challenge (Ex-3) did not show any significant results. Based on the results of the present study, both tested formulations are promising antiviral agents for the treatment of EHV-1 infection.
Subject(s)
Asteraceae/chemistry , Herpesviridae Infections/virology , Herpesvirus 1, Equid , Plant Extracts/therapeutic use , Quercetin/therapeutic use , Acyclovir/analogs & derivatives , Acyclovir/therapeutic use , Administration, Intranasal , Animals , Antiviral Agents/therapeutic use , Disease Models, Animal , Female , Guanine , Herpesviridae Infections/drug therapy , Horses , Mice , Mice, Inbred C57BL , Phytotherapy , Plant Extracts/chemistry , Random AllocationABSTRACT
The study was conducted to investigate the effect of Yinhuangerchen mixture (YM) on Avian infectious laryngotracheitis (AILT) induced by artificial infection and provide a scientific basis for its clinical application. A total of 200 chickens were challenged with infectious laryngotracheitis virus (ILTV). At 72 h post-challenge, the chickens were treated with different doses of YM or the Chinese herbal medicine Houyanjing powder. The relative expression of ILTV, the pathological changes of trachea, and the number of SIgA-secreting cells were detected. Thin-layer chromatography results confirmed that the YM contained Scutellaria baicalensis, Flos lonicerae, Pericarpium citri reticulatae, and Liquorice. The AILT model was successfully established by artificial infection. In the high-dose YM group (HD) and middle-dose YM group (MD), the effective rate of treatment was 100 and 96.7%, respectively, and the overall cure rate was 83.3%. In addition, the results of necropsy showed that the degree of tissue damage in chicken trachea was relatively low. Compared with positive control group, HD and MD chicken had lower relative expression of ILTV but more SIgA-secreting cells. In conclusion, YM can reduce ILTV level in tissue, mitigate tissue damage caused by infection, and enhance mucosal immunity having obvious therapeutic effect on AILT.
Subject(s)
Chickens , Drugs, Chinese Herbal/therapeutic use , Herpesviridae Infections/veterinary , Poultry Diseases/drug therapy , Animals , Dose-Response Relationship, Drug , Herpesviridae Infections/drug therapy , Herpesviridae Infections/virology , Herpesvirus 1, Gallid/drug effects , Poultry Diseases/virology , Random AllocationABSTRACT
Cyprinid herpesvirus 3 (CyHV-3) or koi herpesvirus (KHV) is a virulent viral infection in common carp and koi. The disease has caused global epizootic and economic loss in fish aquaculture and in the wild. Clinacanthus nutans (Burm. f.) Lindau is a well-known medicinal plant used in Thai traditional medicine. Virucidal effects of the plant extract against human herpes simplex virus have been reported. In this study, C. nutans crude extract was tested for antiviral activities against CyHV-3 in koi carp. Results showed effective antiviral activity against CyHV-3 pre- and post-infection. The 50% lethal concentration (LC50 ) of extract was higher than 5 mg/ml. The 50% effective dose (ED50 ) was 0.99 mg/ml, 0.78 mg/ml, 0.75 mg/ml and 0.71 mg/ml at 1, 2, 3 and 4 hr pre-infection, respectively. The ED50 from post-infection tests was 2.05 mg/ml and 2.34 mg/ml at 0 and 24 hr, respectively. These results demonstrated that crude extract expressed antiviral activity against CyHV-3 and can be applied as a therapeutic agent in common carp and koi aquaculture.
Subject(s)
Acanthaceae/chemistry , Antiviral Agents/therapeutic use , Carps , Fish Diseases/drug therapy , Herpesviridae Infections/veterinary , Herpesviridae/drug effects , Plant Extracts/therapeutic use , Animals , Fish Diseases/virology , Herpesviridae Infections/drug therapy , Herpesviridae Infections/virologyABSTRACT
Objective of the study was to determine the effectiveness of various groups of hepatoprotectors in the treatment of patients with nonalcoholic steatohepatitis (NASH) sufferers of the accident at the Chornobyl NPP following the assessment of metabolic changes and control of persistent infections. MATERIALS AND METHODS: The study included 104 males with NASH, who were sufferers of the Chornobyl disaster and underwent examination and treatment in the conditions of the clinics of the National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine. Analysis of the course of the functional state of the liver before and after treatment with hepatoprotectors was carried out using laboratory methods of investiga tion. RESULTS: Hepatoprotectors of different groups used for the treatment of patients affected by the Chornobyl accident with NASH, differed in their effect on various chains in the pathogenesis of disease. Ursodeoxycholic acid (UDCA) drugs and preparations of holy thistle normalized the functional state of the liver and disorders of fat metabolism. Treatment with essential phospholipids eliminated cytolytic syndrome with a significant decrease in alanine amino transferase (p < 0.05), but increased alkaline phosphatase (p < 0.001), beta lipoproteins (p < 0.05), triglycerides (p < 0.05), the total cholesterol level remained elevated to (7.0 ± 0.8) mmol/L. Amino acid (AA) preparations normal ized the level of aminotransferases, eliminated the symptoms of cholestasis with a significant decrease in bilirubin (p < 0.001) and alkaline phosphatase (p < 0.001), positively influenced on fat and carbohydrate metabolism decreasing levels of beta lipoproteins (p < 0.05), triglycerides and glucose. Treatment with hepatoprotectors posi tively influenced on the state of antioxidant protection (AOP) - decreased before treatment in 56.5 % of patients, after treatment it reduced to 28.6 % (p < 0.05), the number of patients with elevated lipid peroxidation indices decreased from 39.1 % to 21.4 %. Titres of antibodies to persistent herpes virus infections, elevated before treat ment, under the influence of hepatoprotectors did not decrease to reference values. CONCLUSION: The most effective were drugs on the basis of AA, when applied they normalized the functional state of the, fat and carbohydrate metabolism, decreased lipoperoxidation and improved AOP state. Effect of drugs AA and UDCA on the level of antibodies to herpesvirus infection requires further study.
Subject(s)
Chernobyl Nuclear Accident , Herpesviridae Infections/drug therapy , Non-alcoholic Fatty Liver Disease/drug therapy , Occupational Exposure/adverse effects , Protective Agents/therapeutic use , Radiation Exposure/adverse effects , Radiation Injuries/drug therapy , Alanine Transaminase/blood , Alkaline Phosphatase/blood , Amino Acids/therapeutic use , Bilirubin/antagonists & inhibitors , Bilirubin/blood , Cholesterol/blood , Cnicus/chemistry , Emergency Responders , Herpesviridae Infections/blood , Herpesviridae Infections/etiology , Herpesviridae Infections/pathology , Humans , Lipid Metabolism/drug effects , Lipid Metabolism/radiation effects , Lipoproteins, LDL/blood , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver/radiation effects , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/pathology , Phospholipids/therapeutic use , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Prospective Studies , Radiation Injuries/blood , Radiation Injuries/etiology , Radiation Injuries/pathology , Triglycerides/blood , Ursodeoxycholic Acid/therapeutic useABSTRACT
Reporting of clinical trials results for Proteflazid® in the drug formulation suppositories and vaginal swabs soaked in the solution of the drug to the local immunity of the female reproductive tract. AIM: The aim of study was to examine the state of local immunity in the reproductive tract of women with sexually transmitted diseases caused by human papillomavirus, herpes viruses (Type 1, 2) and mixed infection (herpes viruses + chlamydia). MATERIALS AND METHODS: The trials involved 216 women with viral sexually transmitted diseases: Cervical Dysplasia associated with papillomavirus infection (HPV) (Group 1); Herpes genitalis type 1 (HSV- 1) and type 2 (HSV-1) (Group 2); mixed infection - HSV-1, HSV-2 and chlamydia (Group 3). RESULTS: Treatment results have confirmed that Proteflazid® contributes to sustainable performance improvement of basic factors of local immunity - sIgA, lysozyme and complement component C3 in the cervical mucus for all three groups of women. CONCLUSIONS: Proteflazid® enhances level of local immunity markers (sIgA, lysozyme, C3 complement component) and improves their ratios. Also it intensifies anticontagious activity of mucosal protection and female reproductive system as whole, during treatment diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections (herpesvirus and chlamydia).
Subject(s)
Chlamydia Infections/drug therapy , Coinfection/drug therapy , Herpesviridae Infections/drug therapy , Immune System/drug effects , Papillomavirus Infections/drug therapy , Plant Extracts/therapeutic use , Sexually Transmitted Diseases/drug therapy , Coinfection/microbiology , Coinfection/virology , Female , Female Urogenital Diseases/drug therapy , Female Urogenital Diseases/microbiology , Female Urogenital Diseases/virology , Herpesvirus 1, Human/drug effects , Herpesvirus 2, Human/drug effects , Humans , Papillomaviridae/drug effects , Plant Extracts/pharmacology , Plants, Medicinal , Poaceae , Sexually Transmitted Diseases/microbiology , Sexually Transmitted Diseases/virology , Treatment OutcomeABSTRACT
Herpes simplex is a disease that is widely distributed throughout the world. It is caused by herpes simplex virus type 1 (HSV-1) and simplex virus type 2 (HSV-2). The drugs of choice for treatment are acyclovir (ACV), Penciclovir (PCV) and other guanine analogues, which have the same mechanism of action. However, due to the constant increase of ACV-resistant strains in immunocompromised patients, it is necessary to find new treatment alternatives. It has been shown that natural products are a good alternative for the treatment of these diseases as well as being an excellent source of compounds with anti-herpetic activity, which may be useful for the development of new drugs and act through a mechanism of action different from ACV and PCV. This paper compiles reports on extracts and compounds isolated from plants that have anti-herpetic activity. We present an analysis of the solvents most widely used for extraction from plants as well as cells and commonly used methods for evaluating cytotoxic and anti-herpetic activity. Families that have a higher number of plants with anti-herpetic activity are evaluated, and we also highlight the importance of studies of mechanisms of action of extracts and compounds with anti-herpetic activity.
Subject(s)
Antiviral Agents/isolation & purification , Herpesviridae Infections/drug therapy , Phytotherapy , Plant Extracts/chemistry , Antiviral Agents/therapeutic use , Humans , Plant Extracts/therapeutic useABSTRACT
The review summarizes results of studies of effects of sulfated polysaccharides from seaweed on herpesviruses and the course of herpesvirus infections. Importance of this problem is determined by the prevalence of herpesviruses that can persist in the human body and demonstrate a high degree of immune mimicry and resistance to antiviral agents. A wide range of physiological action of sulfated polysaccharides, receptor agonists of innate and adaptive immune cells, which possess potent antiviral, antioxidant and anti-inflammatory activities, open the possibility of their use for creation of new generation pharmacological substances and agents with associated activity for the treatment of herpesvirus infections.
Subject(s)
Antioxidants/pharmacology , Antiviral Agents/pharmacology , Herpesviridae Infections/drug therapy , Herpesviridae/drug effects , Plant Extracts/pharmacology , Polysaccharides/pharmacology , Seaweed/chemistry , Animals , Antioxidants/therapeutic use , Antiviral Agents/therapeutic use , Humans , Plant Extracts/therapeutic use , Polysaccharides/therapeutic useABSTRACT
Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with B-cell lymphomas including primary effusion lymphoma and multicentric Castleman's disease. KSHV establishes latency within B cells by modulating or mimicking the antiapoptotic Bcl-2 family of proteins to promote cell survival. Our previous BH3 profiling analysis, a functional assay that assesses the contribution of Bcl-2 proteins towards cellular survival, identified two Bcl-2 proteins, cellular Mcl-1 and viral KsBcl-2, as potential regulators of mitochondria polarization within a latently infected B-cell line, Bcbl-1. In this study, we used two novel peptide inhibitors identified in a peptide library screen that selectively bind KsBcl-2 (KL6-7_Y4eK) or KsBcl-2 and Mcl-1 (MS1) in order to decipher the relative contribution of Mcl-1 and KsBcl-2 in maintaining mitochondrial membrane potential. We found treatment with KL6-7_Y4eK and MS1 stimulated a similar amount of cytochrome c release from mitochondria isolated from Bcbl-1 cells, indicating that inhibition of KsBcl-2 alone is sufficient for mitochondrial outer membrane permiabilzation (MOMP) and thus apoptosis during a latent B cell infection. In turn, this study also identified and provides a proof-of-concept for the further development of novel KsBcl-2 inhibitors for the treatment of KSHV-associated B-cell lymphomas via the targeting of latently infected B cells.
Subject(s)
Apoptosis/drug effects , Cyclin D1/metabolism , Cytochromes c/metabolism , Herpesviridae Infections/physiopathology , Herpesvirus 8, Human/drug effects , Peptides/pharmacology , Viral Proteins/metabolism , B-Lymphocytes/cytology , B-Lymphocytes/drug effects , B-Lymphocytes/metabolism , B-Lymphocytes/virology , Cyclin D1/genetics , Drug Evaluation, Preclinical , Gene Expression Regulation, Viral/drug effects , Herpesviridae Infections/drug therapy , Herpesviridae Infections/metabolism , Herpesviridae Infections/virology , Herpesvirus 8, Human/genetics , Herpesvirus 8, Human/physiology , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Viral Proteins/genetics , Virus Latency/drug effectsABSTRACT
BACKGROUND: Feline herpesvirus 1 is a highly contagious virus that affects many cats. Virus infection presents with flu-like signs and irritation of ocular and nasal regions. While cats can recover from active infections without medical treatment, examination by a veterinarian is recommended. Lysine supplementation appears to be a popular intervention (recommended by > 90 % of veterinarians in cat hospitals). We investigated the scientific merit of lysine supplementation by systematically reviewing all relevant literature. METHODS: NCBI's PubMed database was used to search for published work on lysine and feline herpesvirus 1, as well as lysine and human herpesvirus 1. Seven studies on lysine and feline herpesvirus 1 (two in vitro studies and 5 studies with cats), and 10 publications on lysine and human herpesvirus 1 (three in vitro studies and 7 clinical trials) were included for qualitative analysis. RESULTS: There is evidence at multiple levels that lysine supplementation is not effective for the prevention or treatment of feline herpesvirus 1 infection in cats. Lysine does not have any antiviral properties, but is believed to act by lowering arginine levels. However, lysine does not antagonize arginine in cats, and evidence that low intracellular arginine concentrations would inhibit viral replication is lacking. Furthermore, lowering arginine levels is highly undesirable since cats cannot synthesize this amino acid themselves. Arginine deficiency will result in hyperammonemia, which may be fatal. In vitro studies with feline herpesvirus 1 showed that lysine has no effect on the replication kinetics of the virus. Finally, and most importantly, several clinical studies with cats have shown that lysine is not effective for the prevention or the treatment of feline herpesvirus 1 infection, and some even reported increased infection frequency and disease severity in cats receiving lysine supplementation. CONCLUSION: We recommend an immediate stop of lysine supplementation because of the complete lack of any scientific evidence for its efficacy.
Subject(s)
Cat Diseases/virology , Dietary Supplements , Herpesviridae Infections/veterinary , Herpesviridae/classification , Lysine/pharmacology , Animals , Cat Diseases/prevention & control , Cats , Herpesviridae Infections/drug therapy , Herpesviridae Infections/virology , Lysine/administration & dosageABSTRACT
Human cytomegalovirus (HCMV) infection can lead to congenital hearing loss and mental retardation. Upon immune suppression, reactivation of latent HCMV or primary infection increases morbidity in cancer, transplantation, and late stage AIDS patients. Current treatments include nucleoside analogues, which have significant toxicities limiting their usefulness. In this study we screened a panel of synthetic heparin-binding peptides for their ability to prevent CMV infection in vitro. A peptide designated, p5+14 exhibited ~ 90% reduction in murine CMV (MCMV) infection. Because negatively charged, cell-surface heparan sulfate proteoglycans (HSPGs), serve as the attachment receptor during the adsorption phase of the CMV infection cycle, we hypothesized that p5+14 effectively competes for CMV adsorption to the cell surface resulting in the reduction in infection. Positively charged Lys residues were required for peptide binding to cell-surface HSPGs and reducing viral infection. We show that this inhibition was not due to a direct neutralizing effect on the virus itself and that the peptide blocked adsorption of the virus. The peptide also inhibited infection of other herpesviruses: HCMV and herpes simplex virus 1 and 2 in vitro, demonstrating it has broad-spectrum antiviral activity. Therefore, this peptide may offer an adjunct therapy for the treatment of herpes viral infections and other viruses that use HSPGs for entry.
Subject(s)
Heparan Sulfate Proteoglycans/metabolism , Heparan Sulfate Proteoglycans/pharmacology , Herpesviridae/drug effects , Herpesviridae/physiology , Virus Internalization/drug effects , Amino Acid Sequence , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Cells, Cultured , Cytomegalovirus/drug effects , Cytomegalovirus/pathogenicity , Cytomegalovirus/physiology , Drug Evaluation, Preclinical , Heparan Sulfate Proteoglycans/chemistry , Herpesviridae/pathogenicity , Herpesviridae Infections/drug therapy , Herpesviridae Infections/prevention & control , Herpesviridae Infections/virology , Humans , In Vitro Techniques , Mice , Models, Molecular , Molecular Sequence Data , Muromegalovirus/drug effects , Muromegalovirus/pathogenicity , Muromegalovirus/physiology , Protein Structure, Secondary , Virus Attachment/drug effectsABSTRACT
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's disease. Since the discovery of KSHV 20 years ago, there is still no standard treatment and the management of virus-associated malignancies remains toxic and incompletely efficacious. As the majority of tumor cells are latently infected with KSHV, currently marketed antivirals that target the virus lytic cycle have shown inconsistent results in clinic. Nevertheless, lytic replication plays a major role in disease progression and virus dissemination. Case reports and retrospective studies have pointed out the benefit of antiviral therapy in the treatment and prevention of KSHV-associated diseases. As a consequence, potent and selective antivirals are needed. This review focuses on the anti-KSHV activity, mode of action and current status of antiviral drugs targeting KSHV lytic cycle. Among these drugs, different subclasses of viral DNA polymerase inhibitors and compounds that do not target the viral DNA polymerase are being discussed. We also cover molecules that target cellular kinases, as well as the potential of new drug targets and animal models for antiviral testing.
Subject(s)
Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Herpesviridae Infections/drug therapy , Herpesvirus 8, Human/drug effects , Herpesvirus 8, Human/physiology , Virus Replication/drug effects , Animals , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Humans , Treatment OutcomeABSTRACT
Several essential oils exert in vitro activity against bacteria and viruses and, among these latter, herpes simplex virus type 1 (HSV-1) is known to develop resistance to commonly used antiviral agents. Thus, the effects of the essential oil derived from Mentha suaveolens (EOMS) and its active principle piperitenone oxide (PEO) were tested in in vitro experimental model of infection with HSV-1. The 50% inhibitory concentration (IC50) was determined at 5.1µg/ml and 1.4µg/ml for EOMS and PEO, respectively. Australian tea tree oil (TTO) was used as control, revealing an IC50 of 13.2µg/ml. Moreover, a synergistic action against HSV-1 was observed when each oil was added in combination with acyclovir. In order to find out the mechanism of action, EOMS, PEO and TTO were added to the cells at different times during the virus life-cycle. Results obtained by yield reduction assay indicated that the antiviral activity of both compounds was principally due to an effect after viral adsorption. Indeed, no reduction of virus yield was observed when cells were treated during viral adsorption or pre-treated before viral infection. In particular, PEO exerted a strong inhibitory effect by interfering with a late step of HSV-1 life-cycle. HSV-1 infection is known to induce a pro-oxidative state with depletion of the main intracellular antioxidant glutathione and this redox change in the cell is important for viral replication. Interestingly, the treatment with PEO corrected this deficit, thus suggesting that the compound could interfere with some redox-sensitive cellular pathways exploited for viral replication. Overall our data suggest that both EOMS and PEO could be considered good candidates for novel anti-HSV-1 strategies, and need further exploration to better characterize the targets underlying their inhibition.